# Neoadjuvant therapy in non-small cell lung cancer.

**Tumor:** CPNM (cáncer de pulmón)
**Autores:** Grant C, Hagopian G, Nagasaka M
**Revista:** Crit Rev Oncol Hematol (2023)
**PMID:** 37532102 | **PMCID:** —
**DOI:** [10.1016/j.critrevonc.2023.104080](https://doi.org/10.1016/j.critrevonc.2023.104080)
**Fuente:** PubMed (abstract only)

## Relevancia
CPNM resecable tras quimio-inmunoterapia neoadyuvante (CheckMate-816, NADIM, KEYNOTE-671): downstaging mediastínico (ypN0/N1), tasas de pCR ganglionar y supervivencia. Paralelo importante con mama: la conversión nodal patológica predice EFS/OS y orienta la extensión de la disección ganglionar.

## Abstract
Non-small cell lung cancer (NSCLC) stages I-III were previously predominantly treated with surgery and chemotherapy. With the advent of Checkmate-816, neoadjuvant nivolumab and chemotherapy was FDA approved for the treatment of resectable NSCLC. There are several ongoing trials evaluating other neoadjuvant combinations of chemotherapy and immunotherapy as well as targeted therapies towards driver mutations. Here, we review previous clinical trials and discuss current ongoing trials' potential benefits and challenges.

## Acceso
Vía [DOI](https://doi.org/10.1016/j.critrevonc.2023.104080) o suscripción institucional.

---
*Datos de PubMed. Citar: doi 10.1016/j.critrevonc.2023.104080*
